231 related articles for article (PubMed ID: 33772332)
1. Preclinical evaluation of [
Tafreshi NK; Pandya DN; Tichacek CJ; Budzevich MM; Wang Z; Reff JN; Engelman RW; Boulware DC; Chiappori AA; Strosberg JR; Ji H; Wadas TJ; El-Haddad G; Morse DL
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3408-3421. PubMed ID: 33772332
[TBL] [Abstract][Full Text] [Related]
2. 3p-C-NETA: A versatile and effective chelator for development of Al
Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
[No Abstract] [Full Text] [Related]
3. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290
[TBL] [Abstract][Full Text] [Related]
5.
King AP; Gutsche NT; Raju N; Fayn S; Baidoo KE; Bell MM; Olkowski CS; Swenson RE; Lin FI; Sadowski SM; Adler SS; Thiele NA; Wilson JJ; Choyke PL; Escorcia FE
J Nucl Med; 2023 Apr; 64(4):549-554. PubMed ID: 36396453
[TBL] [Abstract][Full Text] [Related]
6. First preclinical evaluation of [
Handula M; Beekman S; Konijnenberg M; Stuurman D; de Ridder C; Bruchertseifer F; Morgenstern A; Denkova A; de Blois E; Seimbille Y
EJNMMI Radiopharm Chem; 2023 Jun; 8(1):13. PubMed ID: 37389800
[TBL] [Abstract][Full Text] [Related]
7. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
9. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.
Lewis JS; Wang M; Laforest R; Wang F; Erion JL; Bugaj JE; Srinivasan A; Anderson CJ
Int J Cancer; 2001 Dec; 94(6):873-7. PubMed ID: 11745491
[TBL] [Abstract][Full Text] [Related]
11. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
12. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
13.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
14. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy.
Das T; Banerjee S; Shinto A; Kamaleshwaran KK; Sarma HD
Curr Radiopharm; 2014; 7(1):12-9. PubMed ID: 24934713
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
16. Response to Single Low-dose
Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
[No Abstract] [Full Text] [Related]
17. Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice.
Klomp MJ; van den Brink L; van Koetsveld PM; de Ridder CMA; Stuurman DC; Löwik CWGM; Hofland LJ; Dalm SU
Life Sci; 2023 Dec; 334():122173. PubMed ID: 37907154
[TBL] [Abstract][Full Text] [Related]
18. Intraindividual comparison of [
Hänscheid H; Hartrampf PE; Schirbel A; Buck AK; Lapa C
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2566-2572. PubMed ID: 33452632
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]